<DOC>
	<DOCNO>NCT02680847</DOCNO>
	<brief_summary>Safety pharmacokinetics abuse-deterrent , extended-release formulation oxycodone hydrochloride sequester naltrexone core child 7-17 moderate-severe pain .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study ALO-02 Children Ages 7-17 With Pain</brief_title>
	<detailed_description>This multicenter , open-label , single-arm study design characterize PK evaluate safety ALO-02 child adolescents 7 17 year age require opioid analgesia moderate-to-severe pain . The study consist 4 study period ( screen , titration , maintenance , follow-up ) occur period 9 week . The study enroll approximately 140 child adolescent least 100 subject stabilize titration period complete minimum 2 4 week study duration maintenance period satisfy PK endpoint . A safety follow-up visit require 1 week post-last dose .</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Children 717 moderate severe pain require around clock treatment opioid analgesic . Be experience opioid user , define subject treat opioid therapy , equivalent equal &gt; 6 mg per day oxycodone , period 3 consecutive day immediately prior first day dose . ColumbiaSuicide Severity Rating Scale ( CSSRS ) suicidal ideation behavior past year . Hypersensitivity morphine , naltrexone . A life expectancy ( assessed investigator ) less 6 month longer capable take medication orally . Undergone surgery within 3 day prior first day dosing .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>pain indication</keyword>
	<keyword>control release oxycodone</keyword>
</DOC>